TEVA-PHARMACEUTICAL
8.4.2021 09:02:08 CEST | Business Wire | Press release
Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK.
Introducing Seffalair Spiromax and BroPair Spiromax
The launch of Seffalair Spiromax and BroPair Spiromax further extends Teva’s respiratory portfolio, and provides healthcare professionals another option in treating people living with asthma. Since the launch of DuoResp® Spiromax® (budesonide/formoterol), the Spiromax® inhaler has been well received by healthcare professionals and patients.1,2
Inhaler technique and treatment adherence are key factors in improving outcomes for asthma patients, of which there are an estimated 28 million in the EU.3,4
"We are excited about the European approval of Seffalair Spiromax and BroPair Spiromax, as an important goal of our respiratory franchise is to bring new treatment options to healthcare professionals who support people living with long-term conditions such as asthma,” says Paul Blonk, Head of Teva Respiratory Europe. “We want to empower patients to effectively manage their condition through the medicines we provide, whilst also offering cost-effective treatments to healthcare systems.”
About Seffalair Spiromax and BroPair Spiromax (salmeterol xinafoate / fluticasone propionate)
Seffalair Spiromax and BroPair Spiromax are indicated as a regular treatment for asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonists.
About Teva Respiratory
Teva Respiratory develops and delivers high-quality treatment options for respiratory conditions, including asthma, COPD and cystic fibrosis. The Teva Respiratory portfolio is centred on optimizing respiratory treatment for patients and healthcare providers through the development of novel delivery systems and therapies that help address unmet needs. Teva’s respiratory pipeline and clinical trial program are based on drug molecules delivered in proprietary dry powder formulations and breath-actuated device technologies, as well as a targeted biologic treatment for severe asthma. Through research and clinical development, Teva Respiratory continually works to expand, strengthen and build upon its treatment portfolio to positively impact the lives of the millions of patients living with respiratory disease.
About Teva
Teva Pharmaceuticals Europe makes life-saving and life-improving medicines more accessible for millions of people around the world. We focus on treatments for migraine, conditions of the central nervous system including pain, as well as respiratory conditions like asthma and COPD and have a portfolio in oncology. Our mission is to be a global leader in generics and biopharmaceuticals improving the lives of patients around the globe.
Building on more than a century-old legacy we have an established presence in generics, specialty, over-the-counter (OTC) and active pharmaceutical ingredients (API). With a fully integrated R&D function, strong operational base and global infrastructure and scale we invest millions of dollars to help our scientists find the next breakthrough.
We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 40,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com .
References
- van der Palen et al. Poster presented at the ERS International Congress, Paris, France, September 2018 (PA1020).
- Roche N, et al. J Asthma, 2021; DOI: 10.1080/02770903.2021.1875482
- GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. 392 (10159):1789-858.
- Eurostat. First population estimates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCO Concludes LEAP 2026 with Partnerships and Digital Cooperation Milestones7.9.2026 21:48:00 CEST | Press release
The Digital Cooperation Organization (DCO) concluded its participation at LEAP 2026, during which the State of Palestine signed the DCO Charter, becoming a Signatory Member, and unveiled the Digital Prosperity Plan 2026–2028, co-developed with DCO to advance digital infrastructure and AI readiness, digital government, skills, startups, and SMEs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907201316/en/ DCO Concludes LEAP 2026 with Partnerships and Digital Cooperation Milestones (Photo: AETOSWire) The signing followed the DCO Council’s earlier approval of eight candidate countries. Upon completion of accession procedures, DCO will expand from 16 to 24 Member States, representing approximately 980 million people and paving the way for a billion-strong voice for digital cooperation. Tajikistan is also on track to join the organization as an Associate Member, opening new opportunities to strengthen digital cooperation, acc
LR Health & Beauty Strengthens Its Management Team With Martin Lipp as New Chief Financial Officer (CFO)7.9.2026 15:36:00 CEST | Press release
The LR Health & Beauty GmbH, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, is strengthening its management team: effective 7 September 2026, Martin Lipp takes over as Chief Financial Officer (CFO) and joins the Executive Management Team. In his new role, Martin Lipp will be responsible for Global Controlling & Finance, Legal, IT and Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907262360/en/ Martin Lipp, new CFO of the LR Group “With Martin Lipp, we are gaining a highly experienced international finance executive with extensive expertise in managing and transforming businesses. During the current transition phase, he will enrich the senior management in particular with his strong transformation expertise and excellent know-how in the areas of finance, operations and IT. Together, we will consistently drive forward the implementation of our strategy with
Capcom’s Onimusha: Way of the Sword Sells Over 1 Million Units on Launch Day!7.9.2026 15:00:00 CEST | Press release
– Total series sales surpass 10 million units driven by this first new title in 20 years – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Onimusha: Way of the Sword, the latest title in the series, have surpassed 1 million units on the first day of its release. Driven by the performance of this title, cumulative sales of the Onimusha series have now surpassed 10 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907554827/en/ Onimusha: Way of the Sword key art Onimusha: Way of the Sword, which marks the first new title in the series in over 20 years, is a swordplay action game featuring protagonist Miyamoto Musashi that is set in Edo-era Kyoto. This title enhances the exhilarating sword-based action of the series with cutting-edge technology while also providing a compelling story and beautiful visual depictions. In addition, through several marketing initiatives prior to launch, such as
A2RL Sets New International Benchmark with Europe’s First Five-Car Autonomous Race7.9.2026 14:16:00 CEST | Press release
UAE team Kinetiz wins A2RL’s first race outside of Abu Dhabi during ACI Racing Weekend hosted on Imola’s iconic Autodromo Internazionale Enzo e Dino FerrariWatch the race HERE. The Abu Dhabi Autonomous Racing League (A2RL) completed the first-ever multi-car autonomous race in Europe at the Imola Circuit in Italy on 5 September 2026, as part of ACI Racing Weekend. Kinetiz (UAE) won the League’s inaugural international race, across 12 laps of one of the most technically demanding circuits in world motorsport. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907943650/en/ A2RL Sets New International Benchmark with Europe’s First Five-Car Autonomous Race (Photo: AETOSWire) Organised by ASPIRE, the grand challenges arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), A2RL brings together key players across Abu Dhabi’s autonomous mobility ecosystem, with strategic oversight from the Smart and Autonomous Systems Council
Dubai Chambers to Train 14,000 Private Sector Companies in Agentic AI7.9.2026 12:15:00 CEST | Press release
Dubai Chambers has launched specialised Agentic AI training for more than 14,000 private sector companies, helping businesses build the skills needed to adopt the technology across their operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907193930/en/ H.E. Eng. Sultan bin Saeed Al Mansoori speaking during the launch of the training programme (Photo: AETOSWire) The training forms part of Dubai’s wider programme to transition the private sector towards Agentic AI, launched under the directives of H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister and Minister of Defence of the UAE, and Chairman of The Executive Council of Dubai. Delivered through the new Dubai Chambers Academy, an integrated e-learning platform, the training provides practical guidance on applying Agentic AI in business. Participants will explore tools and solutions that can improve operations, effici
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom